Contrasting Achilles Therapeutics (NASDAQ:ACHL) & DBV Technologies (NASDAQ:DBVT)

Achilles Therapeutics (NASDAQ:ACHLGet Free Report) and DBV Technologies (NASDAQ:DBVTGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Volatility and Risk

Achilles Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Earnings & Valuation

This table compares Achilles Therapeutics and DBV Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achilles Therapeutics N/A N/A -$71.18 million ($1.74) -0.48
DBV Technologies $15.73 million 9.44 -$72.73 million ($0.39) -1.97

Achilles Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Achilles Therapeutics and DBV Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achilles Therapeutics 1 1 1 0 2.00
DBV Technologies 1 0 2 0 2.33

Achilles Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 375.62%. DBV Technologies has a consensus price target of $5.00, suggesting a potential upside of 549.35%. Given DBV Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Achilles Therapeutics.

Profitability

This table compares Achilles Therapeutics and DBV Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Achilles Therapeutics N/A -42.33% -37.49%
DBV Technologies -461.32% -46.33% -35.32%

Insider & Institutional Ownership

56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 0.7% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

DBV Technologies beats Achilles Therapeutics on 7 of the 13 factors compared between the two stocks.

About Achilles Therapeutics

(Get Free Report)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

About DBV Technologies

(Get Free Report)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.